{"id":40281,"date":"2026-06-22T10:04:17","date_gmt":"2026-06-22T08:04:17","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/?p=40281"},"modified":"2026-06-18T11:36:40","modified_gmt":"2026-06-18T09:36:40","slug":"nochmals-spaete-evidenz-fuer-einen-vorteil-von-prasugrel-gegenueber-ticagrelor-oder-clopidogrel-nach-pci-und-das-ticagrelor-paradoxon-cme","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2026\/nochmals-spaete-evidenz-fuer-einen-vorteil-von-prasugrel-gegenueber-ticagrelor-oder-clopidogrel-nach-pci-und-das-ticagrelor-paradoxon-cme","title":{"rendered":"Nochmals: sp\u00e4te Evidenz f\u00fcr einen Vorteil von Prasugrel gegen\u00fcber Ticagrelor oder Clopidogrel nach PCI \u2013 und das \u201eTicagrelor-Paradoxon\u201c [CME]"},"content":{"rendered":"<p>Die perkutane Koronarintervention (PCI) ist weltweit ein sehr h\u00e4ufiger kardiologischer Eingriff. Nach Implantation eines Koronar-Stents ist eine duale Hemmung der Thrombozytenaggregation (DAPT) zur Vorbeugung einer Stent-Thrombose obligat, die neben Acetylsalicyls\u00e4ure (ASS) stets einen P2Y12-Inhibitor umfasst. Seit Jahren stehen drei orale Arzneistoffe zur Verf\u00fcgung \u2013 Clopidogrel, Prasugrel und Ticagrelor \u2013, doch welche den besten Kompromiss zwischen [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Die perkutane Koronarintervention (PCI) ist weltweit ein sehr h\u00e4ufiger kardiologischer Eingriff. Nach Implantation eines Koronar-Stents ist eine duale Hemmung der Thrombozytenaggregation (DAPT) zur Vorbeugung einer Stent-Thrombose obligat, die neben Acetylsalicyls\u00e4ure (ASS) stets einen P2Y12-Inhibitor umfasst. Seit Jahren stehen drei orale Arzneistoffe zur Verf\u00fcgung \u2013 Clopidogrel, Prasugrel und Ticagrelor \u2013, doch welche den besten Kompromiss zwischen [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[684,495,1272,73,71,85,86,498,65,83,84,87,1033,79,2005,6381],"class_list":["post-40281","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-akutes-koronarsyndrom","tag-angina-pectoris","tag-arteriosklerose","tag-clopidogrel","tag-herzinfarkt","tag-koronarangiografie","tag-koronarangiographie","tag-koronare-herzkrankheit","tag-myokardinfarkt","tag-pci","tag-perkutane-koronarintervention","tag-perkutane-transluminale-koronare-angioplastie","tag-prasugrel","tag-ptca","tag-ticagrelor","tag-ticagrelor-paradoxon"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/40281","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=40281"}],"version-history":[{"count":4,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/40281\/revisions"}],"predecessor-version":[{"id":40303,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/40281\/revisions\/40303"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=40281"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=40281"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=40281"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}